These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29915533)

  • 1. Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring.
    Stoessel D; Stellmann JP; Willing A; Behrens B; Rosenkranz SC; Hodecker SC; Stürner KH; Reinhardt S; Fleischer S; Deuschle C; Maetzler W; Berg D; Heesen C; Walther D; Schauer N; Friese MA; Pless O
    Front Hum Neurosci; 2018; 12():226. PubMed ID: 29915533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
    Dickens AM; Larkin JR; Griffin JL; Cavey A; Matthews L; Turner MR; Wilcock GK; Davis BG; Claridge TD; Palace J; Anthony DC; Sibson NR
    Neurology; 2014 Oct; 83(17):1492-9. PubMed ID: 25253748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
    Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
    Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
    Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
    Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deterioration.
    Amatruda M; Petracca M; Wentling M; Inbar B; Castro K; Chen EY; Kiebish MA; Edwards K; Inglese M; Casaccia P
    Sci Rep; 2020 Sep; 10(1):15644. PubMed ID: 32973249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic profiles in relapsing-remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study.
    Shi T; Browne RW; Tamaño-Blanco M; Jakimovski D; Weinstock-Guttman B; Zivadinov R; Ramanathan M; Blair RH
    Metabolomics; 2023 Apr; 19(5):44. PubMed ID: 37079261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olfactory dysfunction in patients with primary progressive MS.
    Schmidt FA; Maas MB; Geran R; Schmidt C; Kunte H; Ruprecht K; Paul F; Göktas Ö; Harms L
    Neurol Neuroimmunol Neuroinflamm; 2017 Jul; 4(4):e369. PubMed ID: 28638852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
    Mult Scler; 2019 Jun; 25(7):947-957. PubMed ID: 29781383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.
    Castelo-Branco A; Landfeldt E; Svedbom A; Löfroth E; Kavaliunas A; Hillert J
    Eur J Neurol; 2019 Apr; 26(4):603-609. PubMed ID: 30414299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
    Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Salter A; Thomas NP; Tyry T; Cutter GR; Marrie RA
    Mult Scler; 2018 Jun; 24(7):951-962. PubMed ID: 28524746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of Polish patients with primary progressive multiple sclerosis.
    Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
    Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific myeloid signatures in peripheral blood differentiate active and rare clinical phenotypes of multiple sclerosis.
    Vakrakou AG; Paschalidis N; Pavlos E; Giannouli C; Karathanasis D; Tsipota X; Velonakis G; Stadelmann-Nessler C; Evangelopoulos ME; Stefanis L; Kilidireas C
    Front Immunol; 2023; 14():1071623. PubMed ID: 36761741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.
    Suhy J; Rooney WD; Goodkin DE; Capizzano AA; Soher BJ; Maudsley AA; Waubant E; Andersson PB; Weiner MW
    Mult Scler; 2000 Jun; 6(3):148-55. PubMed ID: 10871825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis.
    Mutukula N; Man Z; Takahashi Y; Iniesta Martinez F; Morales M; Carreon-Guarnizo E; Hernandez Clares R; Garcia-Bernal D; Martinez Martinez L; Lajara J; Nuñez Delicado E; Meca Lallana JE; Izpisua Belmonte JC
    Stem Cell Res; 2021 May; 53():102319. PubMed ID: 33894548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipidomic UPLC-MS/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis.
    Pousinis P; Ramos IR; Woodroofe MN; Cole LM
    Metabolites; 2020 Sep; 10(9):. PubMed ID: 32911763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis.
    Booth DR; Arthur AT; Teutsch SM; Bye C; Rubio J; Armati PJ; Pollard JD; Heard RN; Stewart GJ;
    J Mol Med (Berl); 2005 Oct; 83(10):822-30. PubMed ID: 16075257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.